NYLIM
TVTX icon

New York Life Investment Management’s Travere Therapeutics TVTX Stock Holding History

New York Life Investment Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-47,105
Closed -$363K – 1294
2024
Q1 		$363K Buy
47,105
+31,913
+210% +$269K ﹤0.01% 1144
2023
Q4 		$137K Sell
15,192
-639
-4% -$4.65K ﹤0.01% 1308
2023
Q3 		$142K Sell
15,831
-2,494
-14% -$35.2K ﹤0.01% 1285
2023
Q2 		$281K Sell
18,325
-2,314
-11% -$42.1K ﹤0.01% 1257
2023
Q1 		$464K Buy
+20,639
New +$439K 0.01% 1113

Other funds holding TVTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

New York Life Investment Management's TVTX Position: Q2 2024 in Review

New York Life Investment Management sold out of Travere Therapeutics (TVTX) in Q2 2024, closing a stake of 47,105 shares — an estimated $363K sold.

New York Life Investment Management first reported a position in TVTX in Q1 2023 and held it in 5 quarters. The position peaked at $464K in Q1 2023. 173 funds tracked by Wall St. Rank hold TVTX as of Q2 2024.

  • New York Life Investment Management reported no remaining Travere Therapeutics position as of Q2 2024 after selling out during the quarter.
  • New York Life Investment Management sold 47,105 Travere Therapeutics shares in Q2 2024, an estimated $363K.
  • New York Life Investment Management first reported a position in Travere Therapeutics in Q1 2023 and held it in 5 quarters.
  • New York Life Investment Management's Travere Therapeutics position peaked at $464K in Q1 2023.
  • 173 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2024.

Based on New York Life Investment Management's 13F filing for Q2 2024, filed 5 Aug 2024.